One assignee dominates this dataset, holding 77 of the 123 records in scope — well over half the field. The next four assignees combine for another 42 records, bringing the top five to 96.7% of all records. This level of concentration means most of the treatment-zone and lenslet-array design space is already claimed by a small number of parties, and any new filer needs to check their draft claims against the leader's portfolio specifically, not just the field in general.

Filings peaked at 60 records in 2019, then dropped to a low base before climbing again — from 2 filings in 2021 to 9 in 2024, a +350% increase over that span. That is the most recent period that can be read reliably, because publication lags filing by roughly 18 months, so 2025 and 2026 figures are still incomplete and should not be read as a slowdown. Taken together, the pattern looks like renewed commercial interest following an earlier boom-and-bust cycle rather than a technology past its peak.

The overwhelming majority — 87.8% of the 123 records — touch IPC subclass G02C, covering spectacles and lens hardware, and 48.0% also touch A61F, which covers implants and prostheses framing for physiological treatment claims. Smaller branches include A61N (electrotherapy and radiation therapy, 10.6%) and thin coverage of diagnostics and healthcare informatics. This tells you the field is still primarily a physical lens-design claim space, with software-based monitoring and diagnostic integration comparatively under-claimed.

The IPC composition shows thin coverage in software-linked monitoring (G16H, 2.4% of records), diagnostic imaging tied to lens fitting (A61B, 2.4%), and modulated optical elements (G02F, 0.8%), compared to the dense 87.8% coverage in core spectacle lens hardware. These thinner branches — particularly wearing-compliance sensing and combination light-therapy approaches — represent areas where the core lens-geometry claims are not already saturated. A first claim in one of these adjacent areas is less likely to collide directly with the dominant assignee's existing estate.

US20250332440A1, filed by NEURORAYS, LLC and published in October 2025, claims a method of ocular photo-bio-stimulation rather than a lens geometry — a different technical route from the treatment-zone and lenslet-array claims that dominate the rest of the dataset. For anyone designing a light-based or combination therapy device, this filing is a specific reference point to check against, since it sits outside the crowded G02C hardware cluster where most existing claims are concentrated. It signals that light-therapy approaches are being actively pursued as an alternative mechanism alongside mechanical defocus lenses.